By September, the company plans to create “an autonomous AI research intern” that can solve a small number of specific research problems. The intern will be a precursor to a fully automated multi-agent system, scheduled to debut in 2028.
In an exclusive interview this week, Jakub Pachocki, chief scientist at OpenAI, talked to me about the plans. Find out what I discovered.
-Will Douglas Haven
Mind-altering substances are (still) falling short in clinical trials
Over the past decade, we have seen growing scientific interest in psychedelic drugs. Compounds like psilocybin—which is found in magic mushrooms—are being explored for all kinds of health applications, including treatment of depression, PTSD, addiction, and even obesity. But two studies released earlier this week show just how difficult it is to study these drugs.
To me, they show how overhyped these substances have become. Know why here.
-Jessica Hamzelau
it Story First appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. Sign up To get it in your inbox every Wednesday.
Read more: What effects do psychedelic drugs do to our brains? AI can help us figure it out
